Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Plasmodium falciparum 3D7	-	504		HT	hexose transporter

Database Links
PlasmoDB	PF3D7_0204700 (Pf3D7)
UniProtKB	Q7KWJ5 (Pf3D7)

Whole Organism Assay Data Linked to This Target
Key to terms and symbols		Click column headers to sort
Ligand Sp. Assay description Type Action Value Parameter Reference TCMDC-125163 PfK1 Plasmodium falciparum K1 P. falciparum strain K1 (PfK1) was isolated in Kanchanaburi, Thailand in 1979. PfK1 can be obtained from the European Malaria Reagent Repository or the Malaria Research and Reference Reagent Resource Center (MR4) and is reported to be a multidrug-resistant strain. ✖ Parasite growth inhibition assay - - 6.0 pEC50 1 ⤷ pEC50 6.0 (EC50 9.7x10-7 M) SYBR Green I assay [1] Lifecycle stages: Plasmodium asexual blood stage (erythrocytic merozoite, trophozoite, erythrocytic schizont) TCMDC-125163 Pf3D7 Plasmodium falciparum 3D7 P. falciparum strain 3D7 (Pf3D7) was derived from isolate NF54 by limiting dilution. The complete genome of Pf3D7 has been sequenced (GenBank: LN999946.1). Pf3D7 can be obtained from the European Malaria Reagent Repository or the Malaria Research and Reference Reagent Resource Center (MR4) and is sensitive to a panel of antimalarial compounds including chloroquine and pyrimethamine. ✖ Parasite growth inhibition assay - - 5.8 pEC50 1 ⤷ pEC50 5.8 (EC50 1.4x10-6 M) SYBR Green I assay [1] Lifecycle stages: Plasmodium asexual blood stage (erythrocytic merozoite, trophozoite, erythrocytic schizont)

Malaria Pharmacology Comments

The P. falciparum hexose transporter (PfHT) mediates glucose uptake, an essential process because the intraerythrocytic stages of the parasite's lifecycle are dependent upon host glucose for energy [2]. PfHT is a member of the SLC2 family of hexose and sugar alcohol transporters but is highly divergent in sequence from all human orthologs, with GLUT1 the most closely related human ortholog, sharing only 28% amino acid identity with PfHT [1]. PfHT shows promise as a target for antimalarial drug development with a focus on identifying compounds that inhibit the parasite permease without impairing function of human SLC2 transporters.